Stifel Nicolaus Reaffirms Their Buy Rating on Idexx Laboratories (IDXX)
Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Idexx Laboratories on January 2 and set a price target of $775.00. The company’s shares closed last Friday at $669.99.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Block covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Zoetis, and Inspire Medical Systems. According to TipRanks, Block has an average return of 5.9% and a 49.87% success rate on recommended stocks.
Currently, the analyst consensus on Idexx Laboratories is a Moderate Buy with an average price target of $792.78.
Based on Idexx Laboratories’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.11 billion and a net profit of $274.61 million. In comparison, last year the company earned a revenue of $975.54 million and had a net profit of $232.84 million
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IDXX in relation to earlier this year. Most recently, in November 2025, Nimrata Hunt, the EVP of IDXX sold 9,425.00 shares for a total of $6,628,983.85.
Read More on IDXX:
